Humana (NYSE:HUM – Get Free Report) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share guidance of approx. $16.00 for the period, compared to the consensus earnings per share estimate of $16.35.
Wall Street Analyst Weigh In
Several research analysts have recently commented on the company. UBS Group reaffirmed a neutral rating and issued a $370.00 price objective (down previously from $530.00) on shares of Humana in a research note on Friday, January 26th. Barclays decreased their price objective on Humana from $356.00 to $310.00 and set an equal weight rating on the stock in a research note on Tuesday, April 2nd. Cantor Fitzgerald reaffirmed a neutral rating and issued a $391.00 price objective on shares of Humana in a research note on Wednesday, April 10th. The Goldman Sachs Group decreased their target price on Humana from $450.00 to $385.00 and set a buy rating on the stock in a research note on Wednesday, April 3rd. Finally, Deutsche Bank Aktiengesellschaft downgraded Humana from a buy rating to a hold rating and decreased their target price for the company from $595.00 to $360.00 in a research note on Thursday, January 25th. Eleven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Humana currently has a consensus rating of Hold and a consensus target price of $454.63.
Check Out Our Latest Report on HUM
Humana Trading Down 3.6 %
Humana (NYSE:HUM – Get Free Report) last announced its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. Humana had a return on equity of 19.44% and a net margin of 2.34%. The firm had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter in the previous year, the business earned $9.38 EPS. The company’s quarterly revenue was up 10.7% on a year-over-year basis. As a group, research analysts predict that Humana will post 16.06 earnings per share for the current fiscal year.
Humana Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.12%. The ex-dividend date is Friday, June 28th. Humana’s payout ratio is currently 17.86%.
Insider Activity at Humana
In related news, Director Jorge S. Mesquita purchased 545 shares of Humana stock in a transaction dated Tuesday, February 20th. The stock was purchased at an average cost of $367.09 per share, with a total value of $200,064.05. Following the transaction, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 0.29% of the stock is owned by company insiders.
About Humana
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Stories
- Five stocks we like better than Humana
- Are Penny Stocks a Good Fit for Your Portfolio?
- High-Yield Texas Instruments Could Hit New Highs Soon
- Health Care Stocks Explained: Why You Might Want to Invest
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Using the MarketBeat Dividend Tax Calculator
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.